# A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

> **NCT06297668** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 42 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Treatment A: BGF MDI HFA
- **DRUG:** Treatment B: BGF MDI HFO
- **DRUG:** Treatment C: BGF MDI HFO
- **DEVICE:** AeroChamber Plus Flow-Vu spacer

## Key facts

- **NCT ID:** NCT06297668
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-29
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-06-11
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297668, "A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06297668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*